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Glomerular distribution of type IV collagen in diabetes by high
resolution quantitative immunochemistry. We examined type IV colla-
gen distribution and density in human diabetic kidneys by quantitative
immunogold electron microscopy. We studied normal kidney transplant
donors and "slow-track" and "fast-track" insulin dependent diabetic
(IDDM) patients. The "slow-track" patients had IDDM for  20 years
and mesangial volume fraction (VvMes/glom) of  0.32. The "fast-
track" patients had IDDM for  20 years and VvMes/glom  0.37.
Renal biopsies were embedded in Lowicryl, reacted with polyclonal
anti-type IV collagen (in the distribution of the classical al(IV) and
a2(IV) collagen chains) and monoclonal anti-a4(IV) collagen chain
antibody followed by gold conjugated secondary antibody. We found,
by morphometric techniques, a decrease in the immunogold densities of
anti-type IV collagen in the subendothelial zone of the GBM in the
"fast-track" IDDM patients. There was a trend towards a decrease in
mesangial matrix (MM) particle density in the "fast-track" (P = 0.07)
but not in the "slow-track" patients. However, because of the marked
increase in MM in the "fast-track" patients, the per glomerulus
estimated quantity of these antigens in MM was increased. In contrast,
the density of a4(IV) collagen chain was increased in the epithelial zone
of the GBM in the "fast-track" IDDM patients. It is not known whether
these changes in glomerular type IV collagen represent markers of
advanced diabetic lesions or whether these changes might be detected
earlier in diabetic patients destined for the later development of serious
lesions.
The hallmark of the renal structural changes of diabetic
nephropathy is extracellular matrix (ECM) accumulation in
glomerular, tubular and interstitial sites. The main glomerular
ECM component is type IV collagen although type V and VI
collagens are also present. Type IV collagen consists of at least
five distinct chains: "classical" [al(IV), a2(IV)] and more
recently described "novel" [a3(IV), a4(IV) and a5(IV)] chains.
Additional ECM components include the laminins, fibronectin,
heparan sulphate proteoglycans, and other minor glycoproteins
[1—6]. Biochemical analyses of human glomerular basement
membrane (GBM) preparations have suggested increased
amounts of type IV collagen and decreased amounts of laminin
in diabetes [7, 8]. However, since preparations of GBM, by
current procedures, contain both GBM and mesangial matrix
(MM) [9], biochemical determinations could reflect the changes
which occur in either or both of these structurally and immu-
nohistochemically distinct regions of the ECM [1—4, 9—14].
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Recent studies of diabetic patients indicate that alterations in
ECM components are not equally distributed throughout the
glomerulus and that alterations in MM may occur indepen-
dently of those in GBM [7, 10].
Antibodies to al(IV) and a2(IV) collagen chains of type IV
collagen localize along the subendothelial aspect of the GBM
and throughout the MM, whereas antibodies to a3(IV) and
a4(IV) collagen chains localize throughout the entire thickness
of the GBM but not in MM [(3, 10—12, 15—18]. The localization
of these ECM components in normal human kidney does not
appear to be the same as that proposed by animal studies
[19—23].
It is well known that not all diabetic patients progress to overt
renal disease. This suggests that it may be important to differ-
entiate those renal structural changes which occur in all diabetic
patients, independent of nephropathy risk, from the structural
changes occurring only in patients highly susceptible to the
development of serious lesions. In the current study, we have
performed quantitative immunogold electron microscopy to
estimate the density of type IV collagen chain distributions in
peripheral GBM and MM in insulin-dependent diabetes mellitus
(IDDM) patients and normals. We asked whether there are site
specific alterations in type IV collagen chain distribution pat-
terns or density of labeling which distinguish IDDM patients
who are developing lesions rapidly from patients developing
lesions slowly, if at all. We found decreased density of local-
ization of antibodies to type IV collagen in the distribution of
al(IV) and a2(IV) chains (subendothelial zone of GBM and
MM) in the "fast-track" IDDM patients. In contrast, there was
increased gold particle density for a4(IV) collagen chains in the
epithelial zone of the peripheral GBM in the "fast-track"
IDDM patients.
Methods
Patients
Kidney biopsy tissues were chosen from those available from
a large group of IDDM patients, studied as part of a protocol for
evaluating patients being considered for pancreas transplanta-
tion. The IDDM patients in the current study were selected
from a subset of patients that had tissue appropriately fixed at
the time of biopsy for immunogold electron microscopy. All
patients with such tissues meeting the inclusion criteria were
studied. The criteria were based on severity of glomerular
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Table 1. Clinical characteristics of the study groups
Sex
F1M
Age Duration
years
Ccr
mi/mini
1.73/rn2
UAE
mgi24 hr
Median (Range)
Control 2/4 38 13 — — —(N = 6)
"Slow- 4/2 32 14 26 7 123 32 8(1.5, 1059)
track"
IDDM
(N = 6)
"Fast- 4/2 34 5 14 5 72 27 544 (9, 1226)
track"
IDDM
(N = 6)P <0.01 <0.001
Abbreviations are: Ce,., creatinine clearance; UAE, urinary albumin
excretion; IDDM, insulin-dependent diabetes mellitus; F1M, female/
male.
lesions determined by morphometric analysis and on duration
of diabetes in order to create two nonoverlapping groups as
follows: (1) "slow-track" patients (N = 6): duration of IDDM 
20 years, volume fraction of mesangium (VvMes/glom)  0.32;
(2) "fast track" patients: duration of IDDM 20 years,
VvMes/Glom  0.37. Six biopsy tissues were obtained from
age-matched kidney donors at the time of transplantation sur-
gery and were used to quantify the normal patterns. Character-
istics of the normal and the two patient groups are presented in
Tables 1 and 2.
Measurement of glomerular volume
The point counting method of Weibel and Gomez [24] was
used to measure glomerular volume (Yglom) on light micros-
copy tissues which were fixed in Zenkers solution, embedded in
paraffin, and sectioned and stained with periodic acid-Schiff.
Six to 82 (26 21; X SD) glomerular profiles per patient were
measured.
Preparation and measurement of tissue for electron
microscopy
Routine stereologic techniques, previously described in detail
[6, 25—27] were used to measure mesangial fractional volume
(VvMes/glom), Vv mesangial matrix (MM)/glom), surface den-
sity of the peripheral GBM (SvPGBM), and GBM width.
Peripheral GBM surface per glomerulus (S/G) is the product of
SvPGBM and Vglom.
Antibodies
The antibodies employed in this study are listed in Table 3.
Preparation of tissue for immunogold electron microcopy
Renal tissue obtained by percutaneous needle biopsy in the
IDDM patients or by needle biopsy at transplant surgery in the
controls was immediately examined using a dissecting micro-
scope to ensure that glomeruli were in the tissue samples. Small
cubes (1 mm3) of cortical kidney tissue were immediately fixed
in 4% periodate-lysine paraformaldehyde (PLP) solution for
two hours at 4°C and then washed with 0.025 M phosphate
buffer containing 6% sucrose [14]. The samples were dehy-
drated in a graded ethanol series at progressively lower temper-
atures, down to —35°C, and infiltrated with Lowicryl K4M
(Chemiche Werke Lowi; Waldkraiburg, Germany). The resin
was polymerized at —35°C with long wave ultraviolet radiation.
Ultrathin silver-to-gold interference contrast sections were cut
and mounted on Formvar coated, 100-mesh nickel grids. The
grids were then incubated overnight at 4°C with primary anti-
body. Excess unbound primary antibody was then washed off
the grids using PBS containing 1% BSA and 0.05% Tween-20.
Afterwards, they were exposed to 10 nm gold-conjugated
secondary antibodies for two hours at room temperature and
washed, first with PBS, and then water. The sections were then
stained for 10 minutes with uranyl acetate and five minutes with
lead citrate.
Observation was done with a JEOL 100CX electron micro-
scope. Twenty to 30 photomicrographs were randomly taken
for each glomerulus and enlarged to a final magnification of
about 42,000x. Limitations in the amount of tissue or antibody
available for these studies resulted in not all IDDM patients Or
controls being studied with all of the immunohistochemical
probes.
Measurement of gold particle densities
The density of labeling was expressed as the number of gold
particles per unit area (particles/m2). Peripheral GBM was
defined, as previously described, as that part of the GBM
covered on one side by epithelial cells and on the other side by
endothelial cells with no interposition of mesangial cells or
matrix [27]. Segments of peripheral GBM were randomly cho-
sen and arbitrarily divided into three zones of equal width
(endothelial, middle and epithelial zones; Fig. 1A). This was
done because the limits of the lamina rara interna, lamina densa
and lamina rara externa could not be precisely determined.
Although the inner and outer thirds of the GBM contain the
lamina rarae interna and externa, respectively, some of the
lamina densa was also regularly included in both of these zones.
On the other hand, the middle zone appeared to include only the
lamina densa. A grid consisting of 0.8 cm squares was placed
over each micrograph. The area of each zone of peripheral
GBM sampled was estimated by adding the number of squares
in which the lower left hand corner intersected a given GBM
zone. The number of gold particles labeling each zone of the
GBM was then counted. Mesangial GBM was defined as that
part of the GBM in which one side was covered with epithelial
cells and other side interfaced with mesangial matrix and cells.
The boundary between the mesangial GBM and the mesangium
was roughly drawn to extend from the endothelial edge of the
peripheral GBM, approximating the width of the peripheral
GBM, and paralleling the epithelial edge of the mesangial GBM.
Matrix material internal to these boundaries and to endothelial
cells was considered to be MM. Non-matrix material was
considered mesangial cells (MC). A grid of 1 cm squares was
used to measure MM and MC. The area sampled of each
component was determined by counting the number of times
the lower left hand corner of a square fell on a given compo-
nent. The number of gold particles labeling a given component
within the squares was counted. The same grid was used to
calculate the density of background staining. The densities of
gold particles within the glomerular capillary lumenal and
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Table 2. Morphometric analysis of the study groups
GBM width
nm VvMes/glom VvMM/glom MM/Mes
SvPGBM
sm2Ipin3
Vglom
x1Oim3
S/G
xlO6j.un2
Control (N = 6) 327 39 0.19 0.05 0.08 0.02 0.51 0.09 0.133 0.01 1.375 0.46 0.185 0.066
"Slow-track 660 253 0.27 0.06 0.16 0.05 0.68 0.09 0.104 0.02 1.87 1.06 0.177 0.062
IDDM (N = 6)
"Fast-track" 706 164 0.45 0.08 0.30 0.04 0.72 0.06 0.079 0.02 2.35 0.67 0.182 0.068
IDDM (N = 6)
ANOVA 0.005 0.0001 0.0001 0.005 0.0008 NS NS
C vs. S 0.05 NS 0.05 0.05 0.048 — —
C vs. F 0.05 0.0001 0.0001 0.005 0.008 — —
S vs. F NS — 0.0001 NS NS (0.1) — —
Abbreviations are: IDDM, insulin-dependent diabetes mellitus; C, controls; S, "slow-track" patients; F, "fast-track" patients; NS, not
statistically significant; GBM, glomerular basement membrane; VvMes/glom, mesangial volume fraction per glomerulus; VvMM/glom, mesangial
matrix volume fraction per glomerulus; MM/Mes, the ratio of mesangial matrix volume to total mesangial (matrix + cell) volume; SvPGBM,
surface density of peripheral GBM; Vglom, glomerular volume; S/G, peripheral GBM surface per glomerulus.
Table 3. Characteristics of antibodies used in this study
Antibodies Specificity References/source
Monoclonal antibodies
Mab 85 Human a4(IV)
collagen
chain
[10, 13]
Polyclonal antibodies
Goat anti-type IV Pepsin digested
human
Placental
basement
membrane
Southern Biotechnology
Abbreviations are: Mab, monoclonal antibody; NC, noncollagenous
domain.
a Reactivity of this antibody in human kidneys is identical to those of
antibodies against al(IV) and a2(IV) collagen chains [3, 12]
urinary spaces were calculated and expressed as background
density and subtracted from the densities in the other locations.
Immunogold density values derived here are not presumed to
represent an exact concentration of an antigen in a tissue since:
there is not a 1:1 ratio of gold particles to IgG molecules; there
are differences in antibody affinities and/or titers; and there may
be a partial denaturation of antigenic sites by fixation [28—30].
However, our methods should allow the comparison of relative
site specific densities among the various groups if the conditions
are standardized [31, 32]. To minimize potential problems
caused by day to day variations in fixation schedules, embed-
ding media and incubation protocols, one normal biopsy was
randomly selected to be used as a control to be run each time
that a set of tissues was studied for a given antigen. It was
necessary to overlap these controls and then switch from the
first to the second as we ran out of tissue on the first. Gold
particle densities were corrected for the original control value
by multiplying the densities counted for a set of tissues studied
at a given time by the ratio of the control value first obtained
and the control value obtained with that set of tissues. For the
polyclonal type IV collagen antibody we used the particle
density of mesangial matrix to obtain this ratio. We used
mesangial GBM particle density to standardize for anti-a4(IV)
collagen chain antibody. Results expressed as particle density
have been standardized as described here. The number of
particles per glomerulus were estimated for peripheral GBM
zones as:
SvPGBM x 1/3 GBM width x V glom x standardized
particle density
where SvPGBM = surface density of the peripheral GBM and
Vglom = glomerular volume.
The number of particles per glomerulus were estimated for
mesangial matrix as:
VvMM/glom x Vglom x standardized particle density
where VvMM/glom = volume fraction of mesangial matrix per
glomerulus.
Immunofluorescent microscopy studies have suggested that
antigens for some antibodies, such as anti-a4(IV) collagen
chain, may be unmasked by pretreatment of frozen tissue
sections with 6 M urea, resulting in increased staining intensity
[10]. For this reason we treated Lowicryl sections from two
normal individuals for 20 minutes, 1, 2, 4 and 24 hours with 6 M
urea before incubating them with primary antibody to a4(IV)
collagen chain. We found no significant effect of the 6 M urea
treatment on gold particle densities for a4(IV) collagen chain.
Statistics
Comparisons of the labeling densities and density percentiles
for a given antigen and for a given zone of the GBM mesangial
matrix utilized analysis of variance (Super ANOVA, Abacus
Concepts, Berkeley, California, USA) and differences between
groups evaluated by the Scheffes' test with probabilities for
multiple comparisons. P < 0.05 was considered significant.
Values of P > 0.05 <0.1 were considered indicative of a trend.
Urinary albumin excretion rates, because these data are not
normally distributed, were compared using a nonparametric
(Mann-Whitney U test) test.
Results
Clinical characteristics
Four of six IDDM patients in both the "slow-" and "fast-
track" group were female while two of six controls were female
(Table 1). The ages were similar in all three groups. Duration of
IDDM was, by design, greater in the "slow-track" patients and
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Fig. 1. A. EM photomicrograph of gold labeled antibody to polyclonal anti-type IV collagen antibody in a normal human kidney embedded in
Lowicryl demonstrating the pattern of distribution of the classical [al(JV), a2(IV)J chains of type IV collagen. Note concentration of the gold
particles in the endothelial (EN) zone compared to the middle and epithelial (EP) zone of the glomerular basement membrane (GBM). B. EM
photomicrograph of gold labeled antibody to polyclonal anti-type IV collagen in the mesangial region of a normal glomerulus with distribution of
gold particles on the inner aspect of the mesangial GBM (MGBM) and in mesangial matrix (MM). C. Electron photomicrograph of distribution of
polyclonal type IV collagen antibody in the peripheral capillary wall in a "fast-track" IDDM patient showing persistence of the EN concentration
of the gold particles. L = lumen. D. Electron photomicrograph of polyclonal type IV collagen antibody in the mesangial region of a "fast-track"
IDDM patient showing persistence of the normal pattern of concentration of gold particle distribution on the inner aspect of the MGBM and in MM.
A x35,400; B x49,700; C, D x29,700.
thus not analyzed statistically. Creatinine clearances were track" diabetic patients. Five in the "slow-track" group had
lower (P < 0.01) and urinary albumin excretion rates were normal values for UAE (22 mg124 hr or less), and one had overt
higher (P < 0.001) in the "fast-track" compared to the "slow- proteinuria (UAE > 200 mg/24 hr). In contrast, only one in the
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Table 4. Peripheral glomerular basement membrane polyclonal anti-
type IV collagen particle density
Total
Endothelia
zone
1 Middle
zone
Epithelial
zone
peripheral
GBM
particles!
glomerulusparticles/pin2
Control 141 39 57 21 30 4 4539 1811
(N = 6)
"Slow-track" 86 34 35 19 26 15 6906 3975
IDDM (N =5)
"Fast-track" 55 30 27 17 28 17 4293 1453
IDDM (N = 5)
ANOVA 0.02 NS (0.07) NS NS
Cvs.S NS NS — —
C vs. F 0.03 NS (0.09) — —Svs.F NS NS — —
Abbreviations are: GBM, glomerular basement membrane; IDDM,
insulin-dependent diabetes mellitus; C, controls; S, "slow-track" pa-
tients; F, "fast-track" patients; NS, not statistically significant; N,
number of subjects studied.
"fast-track" group had normal UAE, one had microalbumin-
uria (UAE 45 to 200 mg/24 hr), and four overt proteinuria.
Morphometric analysis
GBM width was increased in both diabetic groups but was
similar between the "slow-" and "fast-track" IDDM patients
(Table 3) VvMes/glom was significantly increased in the "fast-
track" IDDM patients compared to controls, but this was not
true of the "slow-track" IDDM patients. The two diabetic
groups differed in VvMes/glom by design. VvMM/glom was
increased in both diabetic groups compared to controls and was
greater in the "fast-" compared to the "slow-track" IDDM
patients (Table 2) The ratio of mesangial matrix to total mesan-
gial volume (matrix + cell) was increased in both diabetic
groups compared to controls but was similar in the two diabetic
groups (Table 2). SvPGBM was decreased in both IDDM
groups compared to normals, more so in the "fast-track"
patients (Table 2). There were no group differences in Vglom or
S/G.
Immunogold studies
Polyclonal type IV collagen. Labeling of polyclonal antibody
agains classical type IV collagen was concentrated in the
endothelial zone of the peripheral GBM and decreased towards
the epithelial zone in all three groups (Table 4, Fig. 1 A and C).
The labeling appeared uniform throughout the mesangial matrix
and to be more intense than in the GBM (Fig. 1 B and D). The
density of gold particles for polyclonal anti-type IV collagen
was decreased in the endothelial zone of GBM in the "fast-
track" IDDM patients compared to controls (Table 4). Al-
though a similar direction of change was seen in the "slow-
track" patients, this was not statistically significant. The
number of gold particles per glomerulus in each of the three
zones was not different between the groups (data not shown).
Also, there was a trend towards a decrease in density for
polyclonal anti-type IV collagen in the middle zone of the GBM
in the "fast-track" patients versus controls (Table 4). There
was no difference between the groups in the total number of
particles per glomerulus, including all three zones of the periph-
eral GBM (Table 4). There was a trend towards a decrease in
MM particle density in the "fast-track" IDDM patients corn-
Table 5. Mesangial matrix polyclonal anti-type IV collagen particle
density
Matrix density Mesangial matrix
particles/pin2 particles/glomerulus
Control (N = 6) 176 26 4710 2008
"Slow-track" IDDM (N = 5) 154 43 14928 6773
"Fast-track" IDDM (N = 5) 100 53 21675 14915
ANOVA NS (0.07) 0.03
Cvs.S NS NS
C vs. F NS (0.07) 0.03
Svs.F NS NS
Abbreviations are: IDDM, insulin-dependent diabetes mellitus; C,
controls; S, "slow-track" patients; F, "fast-track" patients; NS, not
statistically significant, N, number of subjects studied.
Table 6. Peripheral glomerular basement membrane anti-a4(IV) NC
domain particle density
Endothelial
zone
Middle
zone
Epithelial
zone
particles! pJn2
Control (N = 5) 13.8 4.8 58.6 10.1 41.6 12.5
"Slow-track" 15.3 8.1 54.1 19.2 42.3 19.8
IDDM (N = 6)
"Fast-track" 21.0 10.0 54.8 23.8 68.8 14.2
IDDM (N =6)
ANOVA NS NS 0.02
Cvs.S — — NS
Cvs.F — — 0.05
Svs.F — — 0.04
Abbreviations are: IDDM, insulin-dependent diabetes mellitus; C,
controls; S, "slow-track" patients; F, "fast-track" patients; NS, not
statistically significant; N, number of subjects studied.
pared to controls, but this was not quite significant (P = 0.07;
Table 5). Despite this, because of the increased volume of MM
per glomerulus, the total number of particles per glomerulus
labeling for polyclonal anti-type IV collagen was increased in
the "fast-track" IDDM patients (Table 5).
o4(IV) collagen chain. Particle density labeling for anti-a4
(IV) collagen chain was concentrated in the middle and epithe-
hal zones of the peripheral GBM in all three groups (Table 6;
Fig. 2 A and C). However, it was increased on the epithelial
side of the GBM in the "fast-track" IDDM patients compared
with the "slow-track" IDDM patients and the controls (Table
6). Peripheral GBM particles per glomerulus were increased in
the "fast-track" IDDM patients compared to controls in all
three zones and in the total peripheral GBM, which included all
three zones (Table 7). There was a trend towards an increase in
the number of particles per glomerulus in the epithelial zone in
"fast-track" versus "slow-track" IDDM patients, but this did
not reach significance (P < 0.09, Table 7). There was no
labeling for anti-a4(IV) collagen chain in the MM in the normals
or in the two diabetic groups (Fig. 2 B and D).
Discussion
We applied quantitative immunohistochemistry using unbi-
ased sampling methods based upon stereologic principles to
examine the site specific distribution and to quantify the relative
density of various type IV collagen chains in human biopsy
materials from normal and from IDDM patients with slow and
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Fig. 2. A. Electron microscopic (EM) photomicrograph of an immunogold marker of the distribution of anti-S(IV) collagen in the peripheral
capillary wall of a normal human kidney embedded in Lowicryl. Gold particles are distributed throughout the glomerular basement membrane
(GBM) but concentrated in the middle zone and are relatively sparse in the endothelial (EN) and epithelial (EP) zones of the GBM. B. EM
photomicrograph of an immunogold marker of the distribution of anti-a4(IV) collagen in mesangial region of a normal human glomerulus. Note that
gold particles are restricted to the mesangial GBM (MGBM) and completely absent from mesangial matrix (MM). C. EM photomicrograph of an
immunogold marker of the distribution of anti-a4(IV) collagen in the thickened GBM of a "fast-track" IDDM patient. Note distribution of gold
particles mainly in the EP and middle zones of the GBM with less particles in the EN zone of the GBM. D. EM photomicrograph ofan immunogold
marker of the distribution of anti-a4(IV) collagen in a "fast-track" diabetic patient with restriction of the gold particles to the MGBM and, as in
the normal, absence of gold particles from MM. A x28,lOO; B x29,700; C, D x32,400.
with rapid development of a crucial lesion of diabetic nephrop- exclusively in the pattern of al(IV) and a2(IV) collagen chains
athy [6]. [9, 11, 121 was found to be concentrated in normals in the
A polyclonal antibody to type IV collagen, which localized endothelial third of the GBM and to decrease in density towards
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Table 7. Anti-a4(IV) NC domain peripheral glomerular basement
membrane particles per glomerulus
Endothelial Middle Epithelial
zone zone zone T•ota
peripheral
GBMparticles/glomerulus
Control 157 66 1178 567 735 439 2141 935
(N=5)
"Slow-track" 621 332 1603 761 1654 840 3878 1890
IDDM
(N = 6)
"Fast-track" 828 483 2724 1142 2948 1106 6540 2680
IDDM
(N = 6)
ANOVA 0.03 0.04 0.005 0.02
Cvs.S NS NS NS NS
C vs. F 0.03 0.05 0.005 0.02
S vs. F NS NS NS (0.09) NS
Abbreviations are: GBM, glomerular basement membrane; IDDM,
insulin-dependent diabetes mellitus; C, controls; S, "slow-track" pa-
tients; F, "fast-track" patients; NS, not statistically significant; N,
number of subjects studied.
the epithelial third of the GBM. Also, this antibody localized in
normals uniformly throughout the MM. These findings confirmed
previous reports from animal [31] and human [11, 33] studies.
These distribution patterns were maintained in IDDM pa-
tients. However, the density of gold particles for classical type
IV collagen was significantly decreased in the endothelial zone
of the peripheral GBM, and tended to be decreased in the
middle zones of the GBM and in MM of the "fast-track" IDDM
patients. The particles per glomerulus in the MM increased in
the "fast-track" IDDM patients while particles per glomerulus
in each of the three GBM zones remained unchanged. These
data are consistent with the idea that classical type IV collagen
makes up a smaller proportion of the mass of the MM and the
subendothelial zone of the peripheral GBM in IDDM patients
with the rapid development of marked mesangial expansion.
These data also suggest that other ECM molecules are accumu-
lating in the expanding MM and GBM of IDDM patients.
Candidate molecules for MM include fibronectin, laminin, type
VI collagen, and late in the course of the disease types I and III
collagen. Despite the decrease in particle density, the total
number of gold particles per glomerulus signaling the localiza-
tion of polyclonal anti-type IV collagen antibody was increased
in MM in the "fast-track" IDDM patients, reflecting the
marked MM expansion in these patients and indicating an
accumulation of these molecules at this site in patients with
severe lesions.
Makino et al performed quantitative immunogold electron
microscopy with anti-bovine type IV collagen antibody in five
non-insulin dependent diabetic patients whose disease catego-
rizations were said to range from mild to severe [34]. They
found decreased particle density in the thickened GBM and
particle density which was unchanged from normal in the
expanded mesangium of these patients. However, these studies
are difficult to compare with ours because the site specificity in
normals of the anti-type IV collagen antibody of Makino et al
showed much greater particle density in the middle zone of the
GBM than in the region of the lamina rara interna. This differs
markedly from our findings and from the known distribution of
classical type IV collagen chains in normals using immunoflu-
orescence microscopy [3, 10] or immunogold electron micros-
copy with highly specific monoclonal reagents (Zhu D et al,
unpublished data).
Previous immunofluorescence [4, 10] and immunohistochem-
ical [35] studies have suggested increased amounts of type IV
collagen in the mesangium in diabetic patients, which diminish
only as the lesions, especially of the nodular type, became far
advanced. Here we will try to reconcile these observation with
those of the current study where the density of MM gold
particles indicating the presence of "classical" type IV collagen
chains is not increased in the "slow-track" IDDM patients. We
have previously shown that the fraction of glomerular me-
sangium which is occupied by MM as opposed to mesangial
cells is increased in longstanding IDDM patients whether or not
VvMes/glom is increased [36]. Thus, even though the VvMes/
glom was not significantly increased in the "slow-track" pa-
tients in the present study, MM volume fraction and the ratio of
MM volume to total mesangial volume (matrix + cells) was
increased. At the resolution of the light microscope we hypoth-
esize that this structural change in the "slow-track" patients
provides for the subjective perception of greater intensity of
staining, while in fact, antigen density in mesangial matrix, as
revealed by quantitative immunogold EM, is not changed. If
correct, this hypothesis suggests that great caution is required
in the interpretation of subjective semiquantitative light micro-
scopic antibody labeling studies of extracellular matrix material
in diabetes and in other diseases.
It is not likely that the changes in antigen density found in the
present studies are due to modifications of the type IV collagen
molecules, for example, by glycosylation. Firstly, there are no
studies suggesting that glycation of ECM molecules interferes
with their ability to interact with antibodies. Secondly, it would
be difficult for the hypothesis that ECM glycation causes
interference with ECM-antibody interactions to explain why
there was decreased density of polyclonal anti-type IV collagen
antibody localization in the endothelial zone and unchanged
density in the epithelial zone of the GBM. Glucose is so small a
molecule as to be expected to be unhindered across the entire
glomerular capillary wall. Similarly, this hypothesis would not
explain why density of a4(IV) collagen chain is increased in the
GBM of the "fast-track" IDDM patients.
Anti-a4(IV) collagen chain antibody localized predominantly
in the middle zone, and less in the epithelial and endothelial
zones of peripheral GBM in both normal and "slow-track"
IDDM patients. This is true despite the marked thickening of
the GBM in the "slow-track" IDDM patients. In contrast
a4(IV) collagen chain was present predominantly on the epithe-
hal zone of the thickened GBM and gradually decreased to-
wards the endothehial zone of the GBM in the "fast-track"
IDDM patients. Since GBM width was increased similarly in
the "slow-track" and "fast-track" IDDM patients, it is unlikely
that the increased a4(IV) collagen chain density in the epithelial
zone or particle counts per glomerulus in the peripheral GBM of
the "fast-track" patients could alone explain GBM thickening.
The fact that the "slow-track" patients with even longer
duration of IDDM than the "fast-track" patients had similar
densities of a4(IV) collagen chains in the three GBM zones as
the normal group suggests that the alterations seen in the
"fast-track" IDDM patients were not duration dependent.
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Either the increased epithelial zone a4(IV) collagen chain
density in the "fast-track" patients is somehow consequent to
the more severe mesangial expansion in this group, or this
abnormality may be an indicator or premonitor of glomerular
biochemical alterations which result in the development of
marked MM expansion. Only longitudinal studies involving
biopsies spaced five or more years apart can answer this
question. Also these cross sectional studies cannot answer
whether these alterations are due to increased production,
decreased degradation or both of a4(IV) collagen chain in the
epithelial zone.
We have previously shown that a3(IV) and a4(IV) collagen
chains have identical glomerular distributions in normal human
kidney tissue [3, 12]. Desjardins et al found polyclonal anti-
a3(IV) localized in both the GBM and the MM in normal and
diabetic rats [311. These results suggest that there are important
differences in the site specific distribution of ECM components
in rats compared to humans and illustrate the serious limitations
of generalizations from animal to human studies. It is thus likely
that the altered dynamics of ECM production and/or break-
down which lead to diabetic nephropathy in humans will need
to be explored in humans for a full understanding of the
mechanisms involved.
In summary, there is a decrease in the immunohistochemical
electron microscopic estimates of the density of classical type
IV collagen in MM and in the subendothelial zone of the GBM
in IDDM patients rapidly developing serious lesions of diabe-
tes. In contrast, the density of a4(IV) collagen chain was
increased in the epithelial zone of the GBM in these "fast-
track" IDDM patients. It is not known whether these alter-
ations are markers of advanced diabetic lesions or whether
earlier detection of these abnormalities in diabetic patients
could predict the later development of serious lesions. These
studies suggest limitations of conventional immunohistochemi-
cal methods of studying ECM alterations in disease, illustrate
important differences between animals and humans, and em-
phasize the importance of studies in humans.
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